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Introduction 
Throughout the human body cells grow and die at di±lerent rates. Each tissue has 
specific cellular requirements that define the growth and death of its cells. For example 
red blood cells are replaced frequency whereas brain cells slowly die with age and are not 
replaced. Cancer comes from a fundamental break dovvn in the regulation of growth. 
These new growing cells reach a point when they are too abundant. When they have 
surpassed the body's need tor new cells, they tom1 large masses called tumors. Tumors 
are deadly when they become malignant. Malignant cells have the ability to invade and 
spread throughout other tissues of the body. They can also establish secondary gro\\-th 
areas in a process known as metastasis. Recruiting the blood supply and leaching 
nutrients from other areas of the body, tumors become a burden that ultimately weakens 
the host. A tumor's ability to grow and spread is rarely impeded by the immune S)'Stem. 
This is because tumors have a unique ability to evade the immune system. making cancer 
a silent killer (Damell, 1990). 
Medulloblastoma 
Currently over 20,000 children under the age of 15 in the United States are 
undergoing treatment tor a Brain or _Central Nervous .System (CNS) tumor. Brain tumors 
represent the most common solid tumor of all pediatric cancers. Unfortunately barely 
50% of these patients will survive the upcoming year, with a quarter surviving a decade 
(CBTRUST, 2011 ). The majority of these incidents are in children between 3-7 years of 
age (Gottardo & Gajjar, 2008). Medulloblastomas represent the most common malignant 
pediatric brain tumor with approximately 400 cases annually diagnosed in the United 
States (CBTRUST, 2011). The causation of medulloblastoma is unknown in most 
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patients. Although medulloblastomas occur frequently in patients under 18 years of age, 
they comprise less than 1% of all adult primary CNS tumors (Packer et al., 1999). The 
World Health Organization, or \VHO, classifies medulloblastoma as a primitive 
neuroectodermal tumor (PNET) but distinguishes five subtypes of medulloblastoma: 
classic, anaplastic, large cell, nodular desmoplastic, and medulloblastoma with extensive 
nodularity (Louis et al., 2007). 
Children diagnosed with medulloblastoma five decades ago faced almost certain 
death. Clinical presentation varies with age. usually with signs of iiTitability, vomiting, 
hydrocephalus. tnmcal ataxia, lethargy, and headache. Medulloblastomas appear on CT 
or MRI scans as solid. heterogeneous, contrast-enhancing masses (Khatua et al.. 2012). 
- ~ . . 
The advancements in medulloblastoma outcomes for children represent a successfhl 
achievement for pediatric neuro-oncology. Today's treatment includes surgical resection. 
craniospinal irradiation, and chemotherapy curing 80-85% of children diagnosed with 
average or standard risk medulloblastoma and 70% of those classified with high risk 
disease (Gottardo & Gajjar. 2008). Standard risk patients are over the age of 3 years with 
localized disease and without anaplastic subtype: all other patients are considered high 
risk. Risk stratification in medulloblastoma is currently based on age, metastatic status, 
extent of surgical resection. and histological presence or absence of diffuse anaplasia. 
(Leary & Olson 2012) . 
Unfortunately these impressive improvements in survival are achieved at a high 
cost of quality of life. For this reason patients under 3 years of age are not treated with 
craniospinal radiation, thus contributing to the poor prognosis of these patients. Many 
survivors experience significant long-term neurocognitive and neuroendocrine effects, 
• 
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which are most commonly the cause of the resulting deterioration in patient quality of life 
(Gottardo & Gajjar. 2008). This is due to the standard dose of 23.4 units of absorbed 
radiation, or Gray (Gy), of craniospinal radiation therapy in standard risk 
medulloblastoma patients even though it has been successi1.llly reduced fi·om 36 Gy 
(Leary & Olson 2012). 
Even though the majority of medulloblastoma occur sporadically from cerebellar 
granule nemon precursors that experience immense proliferation and migration 
immediately after birth, there are three known inherited syndromes associated with 
medulloblastoma (Packer et al.. 1999; Hallahan et al., 2004). Gorlin's syndrome is 
characterized by a deregulation of the .S.onic Hedgehog (Shh) pathway. Basal cell nevus 
syndrome patients have also displayed Shh mutations. Turcot syndrome is associated 
vYith a deregulation of the \X/NT gene (Leary & Olson 2012). The Li Fraumeni syndrome 
results in a familial cancer predisposition due to p53 mutations. These genetic 
predispositions for medulloblastoma seem to not affect twins, as it is rarely reported in 
either monozygous or dizygous twins. Medulloblastoma as a whole affects predominately 
males. The understanding of these pathways has inspired the creation of transgenic 
mouse models characterizing the SHH and \VNT pathways (Hatton et aL, 201 0). These 
models provide a background tor the patient derived xenograph mouse models we used. 
Medulloblastoma vs. SPNET 
Both supratentorial primitive neuroectodermal tumors (SPNET) and 
medulloblastoma are primitive neuroectodermal tumors. Initially it was thought that all 
PNETs shared a common origin from primitive neuroectodermal cells (Inda et al., 2006). 
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Primitive cells from which these tumors arise grow in sheets or cords of dense cellularity, 
and are characterized under a microscope by massive nuclei in comparison to the amount 
of cytoplasm present (Inda et al., 2006). This allows for both types of tumor to appear 
under the microscope as small, round, poorly differentiated, cells with large nuclei. 
Despite the histological similarities some studies suggest medulloblastoma and 
SPNETs are genetically dissimilar. Isochromosome 17q is the result of a transverse 
centromere split during mitosis or meiosis that alters the genetic material. It is also the 
most frequent abnormality seen in medulloblastoma. Although SPNET genetics have not 
been comprehensively studied, isochromosome 17q is a rarity in SPNETs (Burnett et al. , 
1997). Another example is the hypermethylation of the CDKN2A locus observed in 
medulloblastoma with a 64% frequency and absent in SPNET. Fomteen percent of 
SPNETs had a loss of 14q. The same loss of 14q was not observed in medulloblastoma. 
In tum, the parched gene located at 9q encodes a tumor suppressor protein that reg1llates 
the Shh pathway: mutations ofthe gene have been found in patients \\ith basal cell nevus 
syndrome. who have an increased risk of medulloblastoma (Burnett et al., 1997). Russo 
et al. noted through comparative genetic hybridization that a loss of genetic material was 
more common than a gain in SPNET. But gain of genetic material was more common in 
medulloblastoma (1999). Even though the genetic studies of SPNETs are quite limited, 
these examples of genetic difference are a small component of fully understanding 
medulloblastoma and SPNET as entirely separate conditions. Research suggests that 
medulloblastoma, not SPNET, arise from cerebellar granule cells (Pomeroy et al., 2002). 
The question arises as to whether or not small cell embryonal tumors in the CNS should 
be categorized together as PNET, or whether medulloblastoma, SPNET, etcetera should 
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be considered independent diseases with different molecular pathways (Inda et al., 2006). 
Judging by the comparative analysis, SPNET and medulloblastoma can be divided into 
two biologically distinct tumor types. 
Supratentorial Primitive Neuroectodermal Tumors 
Although histologically similar to the medulloblastoma, SPNETs are in fact 
distinct entities. SPNETs are a rare childhood brain tumor comprising only 2.5-6.6~/o of 
all pediatric brain tumors, and are extremely rare in adults with only 57 cases ever 
reported worldwide (Raghuram et al. , 2012; Ohba et al., 2008) . These tumors were 
characterized in the 1990s and have not been extensively studied. They present clinically 
similar to medulloblastoma with the exception of the location of the solid, heterogeneous, 
tumor with respect to the tentorial: medulloblastoma is always int1:atentorial. The 
tentorial is the line that separates the cerebellum ±rom the cerebmm. If a tumor is said to 
be infratentorial then it lies in the cerebelhun. SPNETs are divided into two categories: 
pineal and non-pineal tumors. Pineal SPNETs affect the pineal gland. (Biswas et al., 
2009). An SPNET is thought to be less curable than the medulloblastoma because only 
20-30% of diagnosed patients reach the 5-year survival marlc. One explanation of this 
difference is the inability to completely resect supratentorial lesions (Russo et al., 1999). 
In addition to the poor 5-year survival rate, SPNET patients have been reported to have 
30-1 om'fl relapse after standard therapy; no standard treatment exists for relapsed 
SPNETs and their outcome is extremely poor (Butturini, 2009). The current meager 
SPNET overall survival data created a need for this research. 
.. 
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Standard therapy does not exist for SPNETs. Packer et al. set the standard therapy 
for medulloblastoma in 2000, and since then this chemotherapy regimen has been 
adopted to treat other embryonal brain tumors such as SPNET, but to no avail (2000: 
Leary & Olson, 2012). They are treated identically to the high risk medulloblastoma 
patients except for the higher dose of craniospinal radiation of 39 Gy to treat high risk 
individuals. patients>3 years of age (Reddy eta!., 2000). Nevertheless several authors 
have reported SPNETs responding to conventional treatments: for example high-dose 
chemotherapy with autologous bone marrow or stem cell rescue (Chintagumpla et al., 
2009). It is imperative that SPNETs undergo further study so as to establish a standard 
therapy. A xenogratt model was utilized to test novel therapies on SPNETs. 
The biological distinction between medulloblastoma and SPNET along with the 
astounding difference in patient survival created a need this study. We searched for an 
alternative method of treatment for SP~ETs in hopes of significantly improving the 
patient survival and quality of life following treatment. The recent successes with novel 
therapies utilizing kinase inhibitors in other forms of cancer such as breast, prostate, and 
non-Hoclgkin's lymphoma has directed our curiosity to the potential application of these 
types of treatment to embryonal brain tumors and specit!cally SPNETs. (Ramakrishnan et 
al., 2011: Nam eta!.. 2005: Yu eta!., 2001). 
Targeted Kinase Inhibition 
Cell grovvih is a highly regulated process, in which a cell increases it mass, 
duplicates it DNA and then splits into two daughter cells. This progression is known as 
the cell cycle and it is regulated kinase cascades (Darnell, 1990). A kinase is an enzyme 
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that transfers a phosphate group from a donor to an acceptor; in general the A TP acts as 
the donor (Voet et aL 2008). The result of kinase interactions with receptors creates a 
cascade of cellular events, potentially involving multiple pathways. These c.ascades 
regulate the cell cycle progression. Tumors form as a result of the disregulation of the cell 
cycle due to genetic mutations. Activated genes can ultimately increase the frequency of 
cell division causing tumors to grow. Conversely deactivated genes can halt cell division 
and induce programmed cell death, apoptosis, thus causing tumors to shrink (Darnell, 
1990). 
Cell signaling allows cells to communicate and coordinate the growth. death, and 
metabolism of groups of cells. Extracellular chemicals synthesized and released by the 
signaling cell are used to communicate. When these signals are transported to, and 
received by the target cell they cause response triggered by the receptor-signaling 
molecule complex. This response can affect one or multiple pathways in a cascade of 
cellular events leading to a metabolic change. A common theme is the use of a kinase as a 
receptor protein waiting to elicit a response triggered by a phosphate group. The rate of 
the cell cycle can be affected by a disregulation in a regulatory kinase leading to tumor 
metastasis. The web of regulatory pathways is vast and highly intertwined. One pathway 
can elicit a variety of responses from multiple pathways (Darnell, 1990). This makes 
malignant cells difticult to target and kill. 
The traditional chemotherapy methodology is to utilize a general cytotoxic agent 
to eradicate malignant cells. A cytotoxic drug is any compound that inhibits cell 
proliferation within the body. A therapy is detl.ned as cytotoxic when the targeted 
cancerous cells along with the majority of naturally occmTing, rapidly dividing cells are 
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also atiected. Well-known side effects of chemotherapy, such as hair loss and nausea, are 
due to the use of general cytotoxins (Mukhe1jee, 2010). Taking advantage ofthe 
understanding that malignancy is due to regulation errors in the cell cycle, kinase 
inhibitors possess the ability to halt malignant cell growth in either the tumor or 
surrounding blood vessels. If the overactive kinase induces malignant cell grovvih, a 
specific kinase inhibitor can act as a cytostatic agent, suppressing the growth of cells. 
This inhibitor could prevent the tumor cells from growing or prevent angiogenesis and 
cause the tumor to shrink due to a lack of nutrients. 
Dasatinib 
Src family kinases (SFK) have elevated activity levels in numerous human cancer 
cell lines (Nam et al., 2005). SFKs phosphorylate tyrosine residues resulting in the 
activation of oncogenic signal transduction pathways. These pathways regulate tumor 
cell's adhesion, migration. and invasion abilities (Nam et al.. 2005). Dasatinib [N-(2-
chloro-6-methylpheny l)-2-(6-(4-(2-hydroxyethyl)piperazin-1-y I)-2-methy lpyrimidin-4-
ylamino)thiazole-5-carboxamide] is a synthetic. orally available. small molecule inhibitor 
of Src Bcr-Abl family kinases (Tokarski et al., 2006). Its mechanism of action is based on 
its ability to disrupt the oncogenic signal transduction pathways (Nam et al., 2005). 
Dasatinib is FDA approved to treat Philadelphia Chromosome positive patients 
presenting with Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia 
along with currently being studied to treat a variety of other cancers such as prostate: it 
has never been used to treat medulloblastoma in hum<ms. Dasatinib was chosen as an 
agent because of its FDA approval, its ability to cross the blood-brain barrier, and its 
availability at the pham1acy at Seattle Children's (Porkka et al., 2008). 
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Sorafenib 
Vascular endothelial growth factors (VEGFs) and disregulation ofRafpathways 
are vital to angiogenesis and tumor growth. Rafkinases are serine/threonine-specific 
protein kinases that regulate tumor growth and survival (Shiota et aL 2009). Tn contrast, 
VEGFs affect the cell migration and spreading oftumors. Sorafenib [4-[4-[[4-chloro-3 -
( tritluoromethy 1 )pheny 1 ]carbamoylamino ]phenoxy]-N -methy 1-pyricline-2-carboxaminde] 
is a small molecule inhibitor ofVEGF kinases and the Rafkinase. It has exhibited 
anticancer properties in pancreatic, renal, ovarian, and nonsmall cell lung cancer cell 
lines, but has never been used to treat medulloblastoma (Ramakrishnan et al. , 20 11). Akt 
is another serine/threonine kinase that inhibits apoptosis. lt is also involved in glucose 
metabolism, cell migration, and transcription. Sorafenib has also shown Akt inhibition by 
an unknown mechanism in Acute Lymphoblastic Leukemia (Schult et aL 2010). When 
bevacizumab, a single agent VEGF inhibitor, was tested in Non-Hodgkins Lymphoma, 
where VEGFs are over expressed, only a 2% overall response rate was reported. This 
suggests that treatments targeting other pathways along with VEGFs must be utilized in 
combination with VEGF specific therapies (Ramakrishnan et al., 2011 ). 
Thus Sorafenib with its broad antiangiogenic properties and ability to cross the 
blood-brain barrier becomes appealing, especially considering its Raf inhibition as well 
(Lemasson et al. 201 0). With one study goal of oms being to select agents for further 
combination studies in SPNETs, Sorafenib becomes an ideal therapeutic due to its broad 
anticancer properties. 
( 
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Erlotinib 
_Epidermal grov.1:h factors receptors (EGFRs) are regulated by tyrosine kinases 
(Ng et al., 2002). Inactive EGFRs exist in a monomer state and consequently dimerize 
after ligand binding (Voet et aL 2008). This activates the tyrosine kinase intracellular 
domain of the receptor, instigating a cascade of intracellular events (Ciardiello & Tortora, 
20Cll ). The autophosphorylation of the tyrosine kinases is crucial to the activation of 
many EGFRs, even in the absence of an extracellular signal. This is advantageous 
because many different pathways can be affected by a single signal (Voet et al.. 2008). 
Malignant cells secrete Epidermal growth factor; and over-expression of EGFR has been 
shown to contribute to a malignant phenotype in cells (Ng et al., 2002). EGFR signaling 
is crucial for cell cycle progression from 0 1 to S phase. Further studies have shown 
EGFR-mediated signals are active in angiogenesis, metastatic spread, and the inhibition 
of apoptosis. Over-expression of EGFR has been associated with many different solid 
human cancers such as breast, cranial, gastric, prostate, bladder, ovarian, and 
glioblastomas (Ciardiello & Tortora, 2001). By inhibiting EGFR and the consequential 
cascade of events that follow, it would be possible to specifically prevent the proliferation 
of and even kill the malignant cells (Voet et al. , 2008). 
Erlotinib [[ 6, 7 -bis(2~methoxy-ethoxy)-quinazolin-4 y 1-(3 -ethyny lpheny l)amine], 
formerly referred to as OST-774] reversibly inhibits EGFR kinase activity (Ciardiello & 
Tortora, 2001: Ng et al., 2002). Erlotinib's affect on EGFR autophosphorylation in intact 
tumor cells has been shown to induce apoptosis in human colon cancer cells (Ng et al.. 
2002). Previous success against colon and lung tumors has been achieved with Erlotinib 
and cisplatin in human tumor xenographs, and it is currently in a handful of clinical trials 
one example being pancreatic cancer (Ciardiello & Tortora, 2001: Troiani et al., 2012). 
Although gene expression studies of SPNETs have not been conducted to measure 
epidermal gro"'ih factors, the previous efficacy ofErlotinib against a wide variety of 
solid tumor cancers was the basis for its inclusion in this study (Momota et al.. 2008: 
Pomeroy et al., 2002). 
Rapamycin 
12 
Rapamycin [(3S.6R.7E,9R,10R, 12R, 14S, 15E, 17E.19E,21 S23S,26R27R.34aS)-
9,0 1, 12,13,14,21 ,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-
[t 1 R)-2[( 1 S,3R.4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-1 0,21-dimethoxy-
6,8, 12.14,20,26Qhexamethyl-23,27-epoxy-3H-pyrido[2, 1-c] [1.4]~ 
oxaazacyclohentriacontine- LSJ 1 ,28,29(4 H.6H,31 H)-pentone] is a natural product 
isolated from the bacterium Streptomyces hygroscopicus indigenous to Easter Island. It is 
a macrolide antibiotic but has been shown to possesses anti-fungal, immunosuppressive, 
and anti-tumor properties (Yu et al., 200 1). Rapamycin allosterically inhibits the 
mammalian target QfRapamycin (mTOR), a kinase (Yang et al.. 2011). Cell cycle 
progression is regulated by the mTOR protein due to its enhancement of the translation 
initiation complex's interactions with the mRNA s· cap (Yu eta!.. 2001 ). Rapamycin has 
not had overwhelming anti-tumor clinical success due to its instigation of feedback-
activated survi\'al signaling pathways such as Akt phosphorylation (Yang et aL 2001 ). 
This effect bypasses the turned off m TOR protein, and is a result of the cascade of 
cellular events induced by Rapamycin. In order for Rapamycin and its derivative to 
achieve complete Sllceess, mTOR inhibition must be coupled with Akt inhibition, caused 
by Sorafenib, due to the parallel nature of the pathways (Schult et al., 201 0). Similar to 
• 
the targets of the other kinase inhibitors previously mentioned, the mTOR-signaling 
pathway has been t(lund expressed in many human tumors (Yang et a!., 2011 ). This 
makes Rapamycin a potentially successful agent in our study, especially if combination 
studies are implemented. 
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Due to the differences bet\veen medulloblastoma and SPNET, we hypothesized 
that in order for the long-tenn patient survival for SPNET to improve it is possible a 
novel therapy must be utilized. In this study patient-derived xenograft models of SPNET 
were treated with single agent kinases inhibitors in hopes of taking the necessary initial 
steps toward improving long-tenn patient survival and quality of life for patient 
diagnosed with SPNET. 
Materials and Methods 
Patient Derived Xenograph Establishment 
All mice were of the Nu/Nu strain obtained from JAX laboratories and maintained in 
accordance with the NIH Guide for the Care and Use of Experimental Animals. All 
experiments and animal handling were done with the approval ofthe Fred Hutchinson 
Cancer Research Center (FHCRC) Institutional Animal Care and Use Committee 
(lACUC) (TR#1697). Nu!Nu mice are irnmunocompromised, decreasing the likelihood the 
transplant will be rejected by the mouse (Khor et al., 2006). Human tissue samples were 
obtained t1:om Seattle Children's Hospital after they were resected in a surgical procedure 
while the patient was under general anesthesia. The Institutional Review Board (IRB) 
approved the use of resected tumors. The samples were transported to FHCRC packed in 
solid C02 ; they arrived within two hours of the completion of the surgery and were 
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immediately taken to tissue culture. Once under the cell culture hood, the tumor was 
placed in 2-3ml ofDulbecco's Modified Eagle Medium (DMEM: Gibco (Invitrogen) Ne\v 
York) on a 1 Ocm diameter plate. Using a pair of scalpel blades the tumor was gently 
chopped into smaller pieces. Two of these pieces were saved for future analysis; one was 
placed in 10% paraformaldehyde and the other in an Eppendorf tube, which was snap 
frozen at -70°C. The tip of a filtered p 1000 pipette tip was cut so the diameter equaled 
0.7~0.8mm. A normal pipette tip is too narrow to be used to separate the tumor without 
damaging an unacceptable percentage ofthe viable cells. The DMEM solution and tumor 
pieces were pipetted up and down with the cut tip for about 40 cycles. The tumor 
dissociated easily and fell into a single cell suspension. The fibrous tumor portions were 
left intact. A cell strainer (BD Bioscience Maryland. ?O~m1-l OO~tm) was placed in another 
50ml conical tube. The cell suspension including any large pieces were pipetted onto the 
cell strainer. An additional 2-3ml cold DMEM was used to wash the cell strainer. The 
remnants in the strainer were discarded. Using a 10:1 dilution (900pJ DMEM. lOO~tl cell 
suspension) the viable cells in suspension were counted using a Vicell ±1ow cytometer 
(Beckman Coulter California). If the percentage ofviable cells was acceptable (>20{}0) a 
centrifuge was used and the cell suspension was spun at 1 OOOrpm for 5 minutes. 
Afterwards the supernatant was removed. The remaining pellet of cells was resuspended at 
a concentration of 1 Ox 106 cells/ml in cold, senun free, DMEM. Serum-free media was 
used because the recipient mouse provided the necessary serum. The final concentration 
was 5x 106 cells/ml. The equation to calculate the resuspension volume is as follows: 
.ViableCells ( * TotalVolumeCellSuspension(ml)) 
ml , xlOOO(cells/ml). In preparation for 
5x lO (cells I ml) 
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surgery Nu!Nu mice were anesthetized with 600~tl of A vertin (Sigma-Aldrich. St. Louis, 
MO). Each eye was treated with eye ointment to keep the eye hydrated easing the post-
procedure recovery. Surgery began when the mouse no longer responded to a test foot 
pinch. The head and neck were swabbed with an alcohol swab prior to incision. Starting 
between the ears the incision ended at the base of the skull. It was kept as small as 
possible to expedite the healing. Using a drill designed for dental procedures, a small bun 
hole was drilled through the bone. Using a p20 pipette with a 2!J.l tip , 2~tl of the cell 
suspension were injected into the cortex of the cerebrum. Once the pipette tip was 
removed a small piece of SurgiFoam (Seattle Children's Hospital) was placed into the burr 
hole. As the scalp-tissue was pulled back together Tissuemend II (Veterinary Products 
Laboratory, Columbus, Ohio) was placed over the incision to seal it. The mouse was 
placed on a heat mat to help maintain its body temperature during recovety. Additionally 
500!-!1 of saline was injected subcutaneously between the shoulder blades to keep the 
animal hydrated,. The animal was monitored each hour until consciousness was regained: 
it was then placed back into the cage. Three unique patient derived xenograph lines were 
maintained; the subjects for this study were drawn from each of the three lines based upon 
the timing of the appearance of tumors. 
SPNET Flank Allograft 
Once a brain tumor was present in a patient derived xenograft mouse, the mouse 
was euthanized using C02 inhalation. Tumors usually arose after 8 weeks. and the 
animals were sacrificed before symptoms became severe enough to impede the animal's 
quality of life. The tumor was removed and placed in 3-5ml of cold DMEM (or PBS) in a 
50ml conical tube that was placed on ice for transfer to the cell culture facilities. The 
16 
tissue culture procedure was identical to the xenograft establishment methodology, with 
the exception being an equal volume of Matrigel (BD Bioscience Maryland), a substance 
that solidifies at room temperatures, was added to the cell suspension to keep the cells in 
a matrix once injected, improving the percentage of successful injections. This was added 
as a fl.nal step. The fl.nal concentration was 5x106 cells/mi. Using a lml syringe and a 30 
gauge needle the solution was dra¥-n from the conical tube and the syringe placed on ice 
until injection. This increased the survival time ofthe viable cells and prevented the 
Matrigel from solidifYing. Five recipient Nu/Nu mice were anesthetized prior to injection 
with isoflorane inhalant. In the right rear flank of each mouse a subcutaneous injection of 
200~tl (lxl06 cells/ml) was administered (Hallahan et al., 2004; Hatton et aL 2010; 
Hatton et al.. 2006). 
Drug Delivery 
Once the tumor was growing and measurable (>0.5cm), the mouse was enrolled 
into one of the flve study arms, including four treatment am1s and one vehicle control 
arm. A rolling enrollment was used starting with treatment group "A" (Sorafenib) 
followed by group ''B'" (Rapamycin) and so forth until all the study arms had one mouse. 
\Vhen the sixth tumor was large enough for enrollment, group "A" received its second 
animal. This continued until all groups had a sample size of 3. Each mouse was given 
drug by daily gavage therapy for four weeks. Doses were based on FDA approved dosing 
in adult humans and converted to mouse dosing using the NCI dose calculator assuming 
mouse weight of 20 grams. To calculate the dose all mice were assumed to weight 20 
grams. The animals were weighed upon enrollment into the study in order to determine 
their healthy weight. The same dose was given to every adult mouse independent of his 
or her body weight. 
Drug Daily Gavage Dose Dose Administered 
Sorafenib 1.2mglkg 0.24mg 
Rapamycin O.lmg/kg 0.02mg 
Erlotinib l.Smg/kg 0.36mg 
Dasatinib 0.5mg/kg O.lUmg 
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Table 1: Kinase ln hibitors and their •·espective doses based on the NCI dose calculator (Kang et al., 
2011) 
Each dose is based on the NCI calculator, and calculated with the assumption that every mouse weighed 20 
grams. Mice were weighed weekly to monitor health but these measurements did not affect the dose 
administered. 
Approximately 10 doses of each drug were weighed into an Eppendorf tube (refer 
to concentrations above) labeled "Dmg A, Drug B, etc." including a vehicle control. The 
nondescript labels were used to blind the observer who delivered the drug because of his 
or her other role measuring tumor size. Tubes were stored in -20°C. 1% Methyl cellulose 
0.1% Tween 80 solution, the vehicle for drug administration, was added to each tube, 
approximately 1 mL until the desired concentration of the drug was reached. Due to 
insolubility, sonication and vortexing was used to create a suspension. All the drugs are 
soluble in DMSO and ethanol but have very poor solubility in water due to their non-
polar properties. The drug would fall out of suspension and pellet in the bottom of the 
tube. Therefore prior to administration the tubes were vortexed until the pellet was 
grossly resuspended. They were then placed in a sonicater for 1 hour. Once in the 
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procedure room the tubes were vortexed immediately before drawing the drug into the 
syringe. A 1 ml syringe was used to ''slurry" the solution prior to injection. A gavage 
needle was used to administer a 1 OOf.!l oral dose to the mouse. The mice were given daily 
oral gavage treatment for 28 days. Every third day the tumor was measured ,;~,,ith a pair of 
· . (Lenf?th * Widrh 2 ) 
cahpers. To calculate tumor volume the equat10n '-' was used. The 
2 
reason t"l1r squaring the width is to provide an estimate for the depth of the tumor into the 
tissue. 
Tumor Resection and Fixation 
At the conclusion of the 4-week treatment period the mice were euthanized with C02 
inhalation. Tumors were resected from the t1ank for further analysis. Half of the tumor 
was fixed with 1 0% parafonnaldehyde, and the other half was snap frozen at -70°C. 
Tissue blocks were paraffin embedded, cut into 4-~tm sections, and then stained with 
hematox;lin and eosin using standard methods (Hallahan et al.. 2004 ). An outside 
observer blinded from the treatment data evaluated the pathology. 
Statistical .Analysis 
The recorded tumor volumes were analyzed using NCSS 2007 (NCSS Statistical 
Software Utah). A Bonferroni (with control) multiple comparison test with an alpha=0.05 
was used. A Dunnett's Upper and Lower one-sided multiple comparison test were also 
used. Graphs were made using Microsoft Excel (Microsoft, Seattle, W A) and R (Lucent 
Technologies, New Jersey, NJ). 
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Results 
In order to test the etTicacy of novel oral kinase inhibitors in SPNET. xenografts, 
15 mouse flank tumors from three different patient~derived SPNET xenografts were 
enrolled into one of the five treatment am1s. The tumors were treated \Vitl1 the kinase 
inhibitors (Erlotinib. Dasatinib, Rapamycin, and Sorafenib) or the vehicle control for 28 
days via daily gavage. 
Throughout the entire study period the vehicle control vvas found to be 
statistically significant from the other treatment groups (p<0.05) (Fig. 1 ). The Sorafenib, 
Rapamycin, and Dasatinib groups were not found to differ from each other significantly; 
however. the Erlotinib treatment arm did differ significantly from Dasatinib, Rapamycin. 
and Sorafenib (p=0.05) (Fig. 1, 2). All analysis comparing groups was reported using the 
Bonterroni and Dunnett's comparison tests. The proportional tumor volume on the final 
day of treatment exemplifies the difference between the vehicle control and kinase 
inhibitors (Fig. 2). The kinase inhibitor treatment groups showed a slower grmvth rate 
than the vehicle control throughout the study period (Fig. 1 ). This was attributed to 
smaller propmiional tumor volumes on the final day for the kinase inhibitor groups (Fig. 
2). 
The mouse xenografts did resemble human SPNET histologically due to the 
presence ofround. blue cells with large nuclei when stained with hemotoxylin and eosin 
(Fig. 3). The multiple mitotic events in both the vehicle control and Erlotinib treatment 
group also represent a similarity between the xenograft model and SPNET in humans 
(Fig. 3A. 3B). Apoptosis noted in the Erlotinib treatment group is consistent with 
previous tumor response and the induction of apoptosis by Erlotinib (Fig. 3B). The 
tumors seemed to be outgrowing their nutrient supply due to the necrosis seen in both 
kinase inhibitor treated and vehicle control groups (Fig. 3C, 3D). 
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Thus it appears a marked difference was observed between the kinase inhibitor 
therapy and the vehicle control. It suggests Erlotinib, Rapamycin, Sorafenib, and 
Dasatinib wanant further study in SPNET. All kinase inhibitors are potentially successful 
agents to be utilized in combination studies especially the combination of Sorafenib and 
Rapamycin. As a single agent, Erlotinib seems most promising. 
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Figure 1: Growth of treated SPNET tumors throughout entirety of study period 
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Proportional tumor growth of each treatment arm throughout the entire treatment period with n=3 for each 
treatment ann. Tumor volumes have been normalized to themselves to show a proportional growth curve. 
R-squared values for the above regression lines are: Sorafenib (0.7585); Rapamycin (0.9576); Erlotinib 
( 0.0897); Dasatinib (0.9412); Vehicle Control (0.9306). 
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Final Tumor Size by Treatment 
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Figure 2: SPN ET Tumor volumes as measured on final study day group into treatment arms 
The size of each tumor is plotted based on its proportional size compared to the day it was enrolled into the 
study. They are grouped based upon the treatment arm they belonged to. Only tumors that received 
treatment for the entire period are shown. 
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Figure 3: Pathology of sPNET xenogntft tumors after study period stained with hematoxylin and 
eosin (H&E). 
Lighter stained areas of the 1 Ox and 4x images are dead cells bordering the dark live tumor cells. 
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Discussion 
The tlank xenograft model that has been established for the pediatric patient-
derived brain tumors is a useful model for evaluation of novel therapeutics. This is due to 
the successful transplantation and treatment that replicates the previous success with 
medulloblastoma xenografts (Hallahan et al. , 2012). The Nu/Nu immunocompromised 
mice did not reject the tlank tumor. Matrigel was used by Rossi et al. in order to increase 
efficacy of flank xenograft injections, identical to the method of f1ank xenograft 
establishment used in this study (20 1 0). The initial transplant into the cerebrum had been 
previously established; this model is what the xenograft in this study was based upon 
(Hatton et al., 2006). A major difference is the acquisition of tumors. Hallahan eta!. used 
a mouse modified in the SmoAl gene that spontaneously generated medulloblastoma, 
whereas a direct transplant of patient-derived cells into the cerebrum was used in this 
study (2004). Simultaneously Hallahan et al. translated a successful treatment achieved 
by Notch pathway inhibition in the spontaneous medulloblastomas into clinical trials by 
confirming the role of Notch signaling in human medulloblastoma by using RT-PCR on 
the Notch gene (2004). Based on these previous results it can be assumed that the results 
seen in the SPNET xenograft model can be translated to human patients presenting vvith 
SPNET. Hallahan et al. can be used as a reference in directly adapting therapeutic 
successes seen in future xenograft studies to clinical trials; therefore. this model has 
potential for use in evaluation of other pediatric brain tumors with novel therapeutics 
(2004). 
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Due to the marked response seen in the treatment groups, Erlotinib, Sorafenib, 
Dasatinib, and Rapamycin wan·ant fmiher study in SPNET. Their statistical ditlerence 
from the vehicle control treatment ann justifies their use in further combination studies. 
The reactivation ofthe Akt pathway previously seen to limit the Rapamycin's efficacy 
could potentially be solved by combination therapy with Sorafenib (Yu et al., 2001 ). A 
synergistic response has been observed due to a reduction in Akt activation and 
angiogenesis through treatment with Sorafenib (Ibrahim et aL, 2012; Ramakrishnan et aL, 
2012). Erlotinib's unique response from the other treatments could be colTelated to the 
apoptosis seen in the pathology (Fig. 3). The R-squared value of 0.0897 for the Erlotinib 
group suggests nonlinear growth (Fig. 1 ). Although the pathology has not been 
quantified, Erlotinib does have history of inducing apoptosis in colon cancer cells (Fig. 3; 
Ng eta!., 2002). If this is seen consistently in all Erlotinib-treated SPNETs it could be in 
response to EGFR over-expression. Sorafenib has also been known to induce apoptosis 
but the histology has not been completed for the Sorafenib treatment group (Rossi et al.. 
201 0). Thus, Erlotinib and its relationship to EGFR over-expression should be prioritized 
when developing combination therapies along with gene expression analysis. Also a 
combination ofRapamycin with Sorafenib unquestionably warrants h1rther study due to 
the previous success seen when combined. 
Obviously the ultimate goal in a study of this nature is to make the cancer itself 
disappear. Thus far we have only shown a reduction in tumor grov-rth rates. In previous 
studies kinase inhibitors have had limited success clue to other pathways that run parallel 
to the targeted pathway. An example of this is Rapamycin and the Akt pathway it triggers 
via feedback activation (Yu et aL 2001 ). Based upon the assumption that more of these 
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pathways exist without our knowledge, complete success lies in the area of combination 
studies. By combining the single agents, especially Erlotinib, with the other drugs we 
hope to observe complete tumor disappearance in the future. 
As the t1ank tumors presented themselves trom the t!u·ee xenograft lines they were 
assigned to a study group starting with group "A" for the first tumor to present itself; 
group .. B .. for the second tumor, and so forth. This style of randomization was utilized to 
expedite the pace of the study, allowing for each treatment group to obtain a full cohort 
of three animals as rapidly as possible. An issue presented by this style of randomization 
is group "A" theoretically could have obtained the first and sixth fastest growing tumors; 
group "B" the second and seventh fastest, etc. These potential differences in grovvth rates 
could have affected the perceived efficacy of the treatment agents. A simple random 
sampling with a tumor t1:om each xenograft line having the same chance ofbeing selected 
would have been ideal. But due to the period of time required for tumors to present 
themselves this was not feasible in terms of time. 
Erlotinib, Rapamycin, Dasatinib and Sorafenib have previously been used to treat 
mouse xenograft models. A major difference seen in this study when compared to others 
is the dose concentrations. Sorafenib was administered via oral gavage in 200f.Al doses 
(Yuen et al., 2011). The 40mg/kg dose used by Yuen et al. is much larger when compared 
to the 0.5mg/kg dose used in this study (2011 ). Even though a response was seen, the 
dose of Sorafenib could be increased in fmiher studies in accordance with the IACUC. 
Dasatinib was administered twice daily via oral gavage at a dose of :25mg/kg (Rossi et aL 
201 0). The vehicle used by Rossi et al. is not mentioned, but similar to Sorafenib the dose 
can be i1icreased in future studies (201 0). Dasatinib was conYersely administered via 
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intraperitoneal (i.p.) injection, but in order to mimic human patients Dasatinib was 
administered orally in this study (Rossi et al., 2010). Even though Dasatinib treatment 
only continued for 7 days, necrosis was also noted when tumors were resected for 
histology (Rossi et aL 2010). Erlotinib has also been used to treat mice via oral gavage at 
1 OOmg/kg, with a vehicle of delivery not noted (Abraham et al., 2011 ). This does is much 
larger than the dose used in this study but there is no mention of a .. sluiTy" technique or 
vehicle. Once solubility issues are overcome the Erlotinib dose could be increased in 
accordance with IACUC. Rapamycin has previously been used to treat mice at 4mg/kg by 
i.p. injection (Wang et al., 2011). Once again this dose is higher than the Rapamycin dose 
used in this study. Overall the oral drug doses were administered at conservative 
concentrations. If needed all the doses could be increased in future studies. 
The methodology of drug delivery poses another enor source. All of the agents 
are insoluble in H20 or other polar solvents such as saline. V./e found that all agents were 
completely soluble in 100% DMSO. Other studies avoid this issue by using i.p. injections 
but oral gavage was used in order to mimic clinical trials as closely as possible (Wang et 
aL 2011: Rossi et aL 2010 ). Due to the known effects of DMSO on DNA at low 
concentrations it was decided not to use DMSO as a vehicle for delivery (Jia, 201 0). In 
other studies Rapamycin was dissolved in 5% polyethylene glycol (PEG) (Sigma) and 
Tween 80 in PBS (Wang et aL 2011 ). Sorafenib was administered in a 30% Captisol 
vehicle (Yuen eta!., 2011 ). Captisol is a [3-cycloclextrin knovvn as SBE-CD: its 
hydrophilic ring structure and slightly hydrophobic interior make it ideal for drug 
delivery (Yuen et aL 2011 ). Captisol could have been an option but instead the ··s]uny .. 
method was developed with obvious flaws using a vehicle similar to Wang et al. with 
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Tween 80 in PBS (2011). The most obvious flaw was the inability to know the exact 
concentration of drug delivered in each treatment. The agents were dosed into tubes 
based on the quantities of 10 daily doses. Vortexing and sonication were utilized to break 
the drug into the smallest particles. During the intensive vortexing and repeated delivery 
using the same tube it is possible some of the active agent was rendered ineffective. The 
assumption was made that over a period of 10 doses the animal would receive an average 
of the desired dose over the 10-day period. But it is possible a portion of the active agent 
was stuck to the sides of the tube and never entered the gavage needle. In future studies if 
Captisol can solve the solubility issue these kinase inhibitors present, it would be possible 
to eliminate the '"slurry" method. All of the agents are normally administered to humans 
in pill form. 
It should be noted that the use of digital calipers represents the largest consistent 
source of error. Wnen the calipers are placed around the tumor the dimensions will vary 
between two different measurers. The ditierence comes from how tightly the measurer 
places the calipers around the tumor. The measurer was consistent throughout the entire 
study period with the exception of a few weekend days. Yuen et al. is one example of 
other studies that used calipers to measure tumor volume with these same restrictions, but 
attempted to conect for them by measuring every two days instead of bi-weekly as in this 
study (20 11 ). Another option that depends on funding would be to use bi-weekly MRI or 
CT scans to measure the tumor. This method would place the mice under the added stress 
of being anesthetized twice a week. The calipers were placed around the tumor as tight as 
possible without altering the natural shape ofthe tumor. But the correct t!t of the calipers 
around the tumor is subjective to each measurer's own personal opinion. This would 
affect the volume calculation ever so slightly. 
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Upon the completed treatment of all subjects the tumors were removed after the 
animal was sacrificed. The pathological review ofthese samples still needs to be 
completed. Quantification of the mitotic events and apoptotic bodies seen in all treatment 
groups is needed. This data will allow for comparisons between groups that can evaluate 
correlation and, potentially in combination with gene expression analysis, causation. The 
analysis of the snap-f1·ozen tissue samples has not been started. The RNA analysis is 
critical in evaluating the link between the efficacy of the agents and their knovv11 
pathways. For example if an over-expression ofEGFR is seen in the snap frozen samples 
it proves causation between Erlotinib and the apoptotic bodies seen. 
Successfully curing solid tumors in an animal model unfortunately does not 
always translate into success in human patients. Eventually the goal is to develop future 
clinical trials based upon the successes that we hope will be achieved with the 
combination studies. This study was the first step in successfl..llly obtaining the cure for 
one type of pediatric cancer that has been eluding physicians for centuries. 
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